Angioplex octa device

This study initially included 588 eyes from 294 healthy, young volunteers who visited the Armed Forces Capital Hospital for a health screening checkup. All subjects underwent comprehensive ophthalmic examinations including a slit-lamp biomicroscopy, refraction,best-corrected visual acuity (BCVA), intraocular pressure (IOP). Additionally, central corneal thickness (NT-530, NIDEK Co., LTD, Gamagori, Aichi, Japan), axial length (IOLMaster, Carl Zeiss Meditec, Dublin, CA, USA) were measured, and OCT and OCTA using the Zeiss Cirrus 5000 (Carl Zeiss Meditec, Dublin, CA, USA) was performed. All subjects underwent a 3 × 3 mm angiography scan in the peripapillary area using the AngioPlex OCTA device from the Zeiss Cirrus 5000 system, without pupil dilation, and no eyedrops or gels were used to degrade the image quality. The excluded subjects were those with a history of systemic disease including diabetes and hypertension, a history of neuro-ophthalmic or retinal disease, media opacity, glaucoma, a history of ocular trauma, an IOP > 21 mmHg, BCVA < 20/25, OCTA scan with an SS < 7, a, and the presence of a segmentation error in the OCTA scan. If both eyes met the inclusion criteria, one eye was randomly selected. Finally, 259 eyes from 259 healthy, young subjects were included in this study.